search
Back to results

An Enhanced Adherence Support Programme for Highly Active Antiretroviral Therapy (HAART) (eASP)

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 3
Locations
South Africa
Study Type
Interventional
Intervention
Enhanced adherence support
Standard adherence support
Sponsored by
Centre for the AIDS Programme of Research in South Africa
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for HIV Infections focused on measuring adherence, treatment, antiretroviral, HAART, HIV, Treatment Naive

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients enrolled in the CAPRISA CAT programme and the CDC.
  • Willing and able to provide written consent to take part in the study.
  • > 18 years of age (to give consent for participation)
  • Eligible for initiation of HAART (currently CD4+ <200)

Exclusion Criteria:

  • Unwillingness or inability to adhere to the study schedule

Sites / Locations

  • CAPRISA eThekwini Clinical Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

enhanced adherence support for patients initiating antiretroviral therapy

standard adherence support

Outcomes

Primary Outcome Measures

suppressed viral load at 9 months
Those participants with suppressed viral load at 9 months will be classed as treatment success, all others will be classed as treatment failures for the purposes of this outcome.

Secondary Outcome Measures

feasibility of E-ASP in this resource constrained setting
Secondly to describe the relationship between adherence and viral load and CD4+counts
describe factors associated with poor/good adherence in this group
describe the relationship between early adherence and adherence at subsequent timepoints
to establish the validity of self-reported adherence (in relation to pill counts) in this context
to assess the long-term impact of E-ASP on adherence
suppressed viral load at 12 months
Those participants with suppressed viral load will be classed at treatment successes, all others will be classed as treatment failures for this secondary outcome measure.
adherence at 6 months

Full Information

First Posted
December 6, 2006
Last Updated
January 29, 2016
Sponsor
Centre for the AIDS Programme of Research in South Africa
Collaborators
Doris Duke Charitable Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00408642
Brief Title
An Enhanced Adherence Support Programme for Highly Active Antiretroviral Therapy (HAART)
Acronym
eASP
Official Title
An Enhanced Adherence Support Programme for HAART
Study Type
Interventional

2. Study Status

Record Verification Date
January 2016
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
March 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre for the AIDS Programme of Research in South Africa
Collaborators
Doris Duke Charitable Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In southern Africa, TB is the most common first AIDS-defining condition. Initiating Antiretroviral therapy (ART) in HIV positive TB patients will lead to the inclusion of the majority of HIV/AIDS patients currently fulfilling the criteria for therapy. Establishing an effective intervention to increase treatment adherence in this group is essential for the successful roll out of ART in the region. This proposed randomized controlled study aims to compare the effectiveness of two adherence support programmes (ASP) for use in patients with HIV-related TB in the context of CAPRISA AIDS Treatment (CAT)programme in KwaZulu-Natal, South Africa; the enhanced adherence support programme (E-ASP) or the standard adherence support programme (S-ASP). S-ASP consists of three counselor presented, group education sessions. E-ASP is an extension of S-ASP and is based on the Information-Motivation-Behavioral Skills (IMB) Model of Adherence to Antiretroviral Therapy, a theoretical model initially developed to reduce HIV risk behavior. The E-ASP will consist of several interconnected components: 1) development and maintenance of an educational and supportive milieu at the CDC Clinic, 2) provision of five structured educational, support and behavioral skills building sessions, and (3) three weekly ART planning sessions.
Detailed Description
Enhanced Adherence Support (E-ASP) All patients will receive sessions one and two of the Standard ASP. Following randomization, the intervention (experimental) arm patients receive the E-ASP described below and the standard of care (control) arm patients receive session three of the S-ASP. Two health educators are employed and trained to administer E-ASP. The goal of the E-ASP is to identify and address patient deficits in information, motivation, and behavioural skills that inhibit consistent and correct self-administration of ARV medications, including those skills required to adhere to the clinic visit schedule. By using specific motivational techniques (Motivational Interviewing) and structured one-on-one sessions, the health educator empower patients to pre-empt situations that have been shown to lead to non-adherence and make plans for situations in which they are less likely to adhere. Components of the E-ASP The E-ASP augments S-ASP and consistS of several interconnected components: 1) development and maintenance of an educational and supportive milieu at the CDC Clinic, 2) provision of five structured education, support and behavioural skills building sessions, and (3) three weekly ART planning sessions. Development and Maintenance of an Educational and Supportive Milieu A separate room is available for exclusive use of the E-ASP. This room has educational materials available at all times, and is a comfortable area for patients to relax and socialize with one another during the course of their time at the CDC clinic. Provision by Study Health Educator of 5 Structured Education, Support, and Behavioural Skills Sessions The educational, support, and behavioural skills building sessions consist of five, one-on-one interactive sessions that will be conducted by the health educator. The sessions take place at five important times during patients' early ART: On the day of commencement of ART - "Preparing to take ART medications" 2 weeks after starting ART - "Adjusting to taking ART medications" 2 months after starting ART - "Feeling good and staying healthy taking ART medications" 3 months after starting ART - "Planning for ongoing HIV care and daily ART medications" 6 months after starting ART - "Preparation for lifelong HIV care and daily ART medications" The content matter (key educational, support and skills points/messages) for the sessions is conveyed by the study health educator using specially designed story board flip charts, put into table-standing easel display books; the front side faces the patient and the backside faces the health educator. Posters including all pertinent images and messages will be put onto the walls for ease of summarizing the information, and for providing an overview of important messages. All messages will also be conveyed in pictorial form to ensure that literacy levels of the cohort do not negatively affect understanding. The other important educational, motivation and skills building tool available is a double-sided Adherence Problem Solving Pocket Card. This tool lists commonly occurring medication adherence problems on the front side and practical solutions/strategies on the back.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
adherence, treatment, antiretroviral, HAART, HIV, Treatment Naive

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
297 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
enhanced adherence support for patients initiating antiretroviral therapy
Arm Title
2
Arm Type
Active Comparator
Arm Description
standard adherence support
Intervention Type
Behavioral
Intervention Name(s)
Enhanced adherence support
Intervention Description
The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
Intervention Type
Behavioral
Intervention Name(s)
Standard adherence support
Intervention Description
The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
Primary Outcome Measure Information:
Title
suppressed viral load at 9 months
Description
Those participants with suppressed viral load at 9 months will be classed as treatment success, all others will be classed as treatment failures for the purposes of this outcome.
Time Frame
9 months
Secondary Outcome Measure Information:
Title
feasibility of E-ASP in this resource constrained setting
Time Frame
one year
Title
Secondly to describe the relationship between adherence and viral load and CD4+counts
Time Frame
2 months, 9 months and 12 months
Title
describe factors associated with poor/good adherence in this group
Time Frame
one year
Title
describe the relationship between early adherence and adherence at subsequent timepoints
Time Frame
2 weeks, and 2 and 9 months after start ART and 12 months
Title
to establish the validity of self-reported adherence (in relation to pill counts) in this context
Time Frame
one year
Title
to assess the long-term impact of E-ASP on adherence
Time Frame
18 months
Title
suppressed viral load at 12 months
Description
Those participants with suppressed viral load will be classed at treatment successes, all others will be classed as treatment failures for this secondary outcome measure.
Time Frame
12 months
Title
adherence at 6 months
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients enrolled in the CAPRISA CAT programme and the CDC. Willing and able to provide written consent to take part in the study. > 18 years of age (to give consent for participation) Eligible for initiation of HAART (currently CD4+ <200) Exclusion Criteria: Unwillingness or inability to adhere to the study schedule
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francois van Loggerenberg, MA(ResPsych)
Organizational Affiliation
CAPRISA, University of KwaZulu-Natal
Official's Role
Principal Investigator
Facility Information:
Facility Name
CAPRISA eThekwini Clinical Research Site
City
Durban
State/Province
KwaZulu-Natal
ZIP/Postal Code
4001
Country
South Africa

12. IPD Sharing Statement

Citations:
PubMed Identifier
16036253
Citation
Amico KR, Toro-Alfonso J, Fisher JD. An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence. AIDS Care. 2005 Aug;17(6):661-73. doi: 10.1080/09540120500038058.
Results Reference
background
PubMed Identifier
24696226
Citation
van Loggerenberg F, Grant AD, Naidoo K, Murrman M, Gengiah S, Gengiah TN, Fielding K, Abdool Karim SS. Individualised motivational counselling to enhance adherence to antiretroviral therapy is not superior to didactic counselling in South African patients: findings of the CAPRISA 058 randomised controlled trial. AIDS Behav. 2015 Jan;19(1):145-56. doi: 10.1007/s10461-014-0763-6.
Results Reference
result
Links:
URL
http://link.springer.com/article/10.1007/s10461-014-0763-6
Description
Primary outcome paper

Learn more about this trial

An Enhanced Adherence Support Programme for Highly Active Antiretroviral Therapy (HAART)

We'll reach out to this number within 24 hrs